Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report

BMC Neurology

Volumn 17, Issue 1, 2017, Pages

  Wallin, A ^a,q   Kapaki, E ^b   Boban, M ^c   Engelborghs, S ^d,e   Hermann, D M ^f   Huisa, B ^g   Jonsson, M ^a   Kramberger, M G ^h   Lossi, L ⁱ   Malojcic, B ^c   Mehrabian, S ^j   Merighi, A ⁱ   Mukaetova Ladinska, E B ^k   Paraskevas, G P ^b   Popescu, B O ^l   Ravid, R ^m   Traykov, L ^j   Tsivgoulis, G ^b   Weinstein, G ⁿ   Korczyn, A ^o   Bjerke, M ^e   Rosenberg, G ^p   more..

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d Memory Clinic   (Belgium)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^k NEWCASTLE UNIVERSITY   (United Kingdom)

^l CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^m Brain Bank Consultants   (Netherlands)

ⁿ UNIVERSITY OF HAIFA   (Israel)

^o TEL AVIV UNIVERSITY   (Israel)

^p UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^q SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Alzheimer's disease; Biomarkers; Blood; CSF; Dementia; Mixed type dementia; Subcortical small vessel disease; Vascular cognitive impairment

Indexed keywords

ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR 7; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; FIBRINOGEN; HOMOCYSTEINE; MATRIX METALLOPROTEINASE; MYELIN BASIC PROTEIN; SULFATIDE; TAU PROTEIN; APP PROTEIN, HUMAN; BIOLOGICAL MARKER;

ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; AXON; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CELL DAMAGE; CELL METABOLISM; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONSENSUS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYPERCOAGULABILITY; NERVE CELL DEGENERATION; NEUROFILAMENT; NEUROPATHOLOGY; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; VASCULAR COGNITIVE IMPAIRMENT; WHITE MATTER LESION; DEMENTIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR DISEASE; WHITE MATTER;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOMARKERS; BLOOD-BRAIN BARRIER; COGNITIVE DYSFUNCTION; CONSENSUS; DEMENTIA; HUMANS; VASCULAR DISEASES; WHITE MATTER;

EID: 85019939736     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-017-0877-3     Document Type: Article

References (157)

1. Erkinjuntti T. Diagnosis and management of vascular cognitive impairment and dementia. J Neural Transm Suppl. 2002;63:91-109.
2. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1(7):426-36.
3. Salvadori E, Poggesi A, Valenti R, Della Rocca E, Diciotti S, Mascalchi M, et al. The rehabilitation of attention in patients with mild cognitive impairment and brain subcortical vascular changes using the attention process training-II. The RehAtt study: rationale, design and methodology. Neurol Sci. 2016;37(10):1653-62.
4. Jia J, Wei C, Liang J, Zhou A, Zuo X, Song H, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: a multicentre, randomized, double-blind, placebo-controlled trial. Alzheimers Dement. 2016;12(2):89-99.
5. Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease. Acta Neuropathol. 2016;131(5):659-85.
6. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125(Pt 4):765-72.
7. Abraham HM, Wolfson L, Moscufo N, Guttmann CR, Kaplan RF, White WB. Cardiovascular risk factors and small vessel disease of the brain: blood pressure, white matter lesions, and functional decline in older persons. J Cereb Blood Flow Metab. 2016;36(1):132-42.
8. Filomena J, Riba-Llena I, Vinyoles E, Tovar JL, Mundet X, Castane X, et al. Short-term blood pressure variability relates to the presence of subclinical brain small vessel disease in primary hypertension. Hypertension. 2015;66(3):634-40. discussion 445
9. Pavlovic AM, Pekmezovic T, Zidverc Trajkovic J, Svabic Medjedovic T, Veselinovic N, Radojicic A, et al. Baseline characteristic of patients presenting with lacunar stroke and cerebral small vessel disease may predict future development of depression. Int J Geriatr Psychiatry. 2016;31(1):58-65.
10. Toyoda G, Bokura H, Mitaki S, Onoda K, Oguro H, Nagai A, et al. Association of mild kidney dysfunction with silent brain lesions in neurologically normal subjects. Cerebrovasc Dis Extra. 2015;5(1):22-7.
11. Toyoda K. Cerebral small vessel disease and chronic kidney disease. J Stroke. 2015;17(1):31-7.
12. Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology. 2014;83(14):1228-34.
13. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999;53(9):1937-42.
14. Dearborn JL, Schneider AL, Sharrett AR, Mosley TH, Bezerra DC, Knopman DS, et al. Obesity, insulin resistance, and incident small vessel disease on magnetic resonance imaging: atherosclerosis risk in communities study. Stroke. 2015;46(11):3131-6.
15. Alagiakrishnan K, Hsueh J, Zhang E, Khan K, Senthilselvan A. Small vessel disease/white matter disease of the brain and its association with osteoporosis. J Clin Med Res. 2015;7(5):297-302.
16. Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: a comprehensive review. Respir Med. 2015;109(11):1371-80.
17. Durgan DJ, Bryan RM Jr. Cerebrovascular consequences of obstructive sleep apnea. J Am Heart Assoc. 2012;1(4):e000091.
18. Makedonov I, Black SE, MacIntosh BJ. Cerebral small vessel disease in aging and Alzheimer's disease: a comparative study using MRI and SPECT. Eur J Neurol. 2013;20(2):243-50.
19. Ortner M, Kurz A, Alexopoulos P, Auer F, Diehl-Schmid J, Drzezga A, et al. Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer's disease. Biol Psychiatry. 2015;77(8):704-10.
20. Kim HJ, Im K, Kwon H, Lee JM, Kim C, Kim YJ, et al. Clinical effect of white matter network disruption related to amyloid and small vessel disease. Neurology. 2015;85(1):63-70.
21. Jang YK, Kwon H, Kim YJ, Jung NY, Lee JS, Lee J, et al. Early- vs late-onset subcortical vascular cognitive impairment. Neurology. 2016;86(6):527-34.
22. Bersano A, Debette S, Zanier ER, Lanfranconi S, De Simoni MG, Zuffardi O, et al. The genetics of small-vessel disease. Curr Med Chem. 2012;19(24):4124-41.
23. Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF, Schultzberg M, et al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci. 2009;283(1-2):99-106.
24. Ueno M, Chiba Y, Matsumoto K, Murakami R, Fujihara R, Kawauchi M, et al. Blood-brain barrier damage in vascular dementia. Neuropathology. 2016;36(2):115-24.
25. Srinivasan V, Braidy N, Chan EK, Xu YH, Chan DK. Genetic and environmental factors in vascular dementia: an update of blood brain barrier dysfunction. Clin Exp Pharmacol Physiol. 2016;43(5):515-21.
26. Wang M, Norman JE, Srinivasan VJ, Rutledge JC. Metabolic, inflammatory, and microvascular determinants of white matter disease and cognitive decline. Am J Neurodegener Dis. 2016;5(5):171-77.
27. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977;37(5):385-90.
28. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-44.
29. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337-52.
30. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I, Svennerholm L. Blood brain barrier function in vascular dementia. Acta Neurol Scand. 1990;81(4):318-22.
31. Wallin A, Sjogren M, Edman A, Blennow K, Regland B. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol. 2000;44(4):229-35.
32. Wallin A, Sjogren M. Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev. 2001;122(16):1937-49.
33. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers Dis. 2011;27(3):665-76.
34. Rosenberg GA, Bjerke M, Wallin A. Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment. Stroke. 2014;45(5):1531-8.
35. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta. 2004;342(1-2):1-12.
36. Levada OA, Trailin AV. [Serum level of S100B as a marker of progression of vascular mild cognitive impairment into subcortical vascular dementia and therapy effectiveness]. Likars'ka sprava/Ministerstvo okhorony zdorov'ia Ukrainy. 2012;2(3-4):53-59.
37. Gao Q, Fan Y, Mu LY, Ma L, Song ZQ, Zhang YN. S100B and ADMA in cerebral small vessel disease and cognitive dysfunction. J Neurol Sci. 2015;354(1-2):27-32.
38. Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, Rudolf S, et al. S-100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord. 2001;66(1):89-93.
39. Dittrich S, Sunyakumthorn P, Rattanavong S, Phetsouvanh R, Panyanivong P, Sengduangphachanh A, et al. Blood-brain barrier function and biomarkers of central nervous system injury in Rickettsial versus other neurological infections in Laos. AmJTrop Med Hyg. 2015;93(2):232-7.
40. Mecocci P, Parnetti L, Romano G, Scarelli A, Chionne F, Cecchetti R, et al. Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. J Neuroimmunol. 1995;57(1-2):165-70.
41. Blennow K, Wallin A, Ekman R. Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders? J Neural Transm Park Dis Dement Sect. 1994;8(3):183-91.
42. Wallin A, Blennow K, Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia. 1996;7(5):267-72.
43. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat Immunol. 2015;16(3):229-36.
44. Holmes C. Review: systemic inflammation and Alzheimer's disease. Neuropathol Appl Neurobiol. 2013;39(1):51-68.
45. Aribisala BS, Wiseman S, Morris Z, Valdes-Hernandez MC, Royle NA, Maniega SM, et al. Circulating inflammatory markers are associated with magnetic resonance imaging-visible perivascular spaces but not directly with white matter hyperintensities. Stroke. 2014;45(2):605-7.
46. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon study. Neurology. 2012;78(10):720-7.
47. Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, et al. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham heart study. Neurology. 2015;84(8):825-32.
48. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam scan study. Circulation. 2005;112(6):900-5.
49. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 2004;61(5):668-72.
50. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, et al. Blood inflammatory markers and risk of dementia: the Conselice study of brain aging. Neurobiol Aging. 2007;28(12):1810-20.
51. Miralbell J, Soriano JJ, Spulber G, Lopez-Cancio E, Arenillas JF, Bargallo N, et al. Structural brain changes and cognition in relation to markers of vascular dysfunction. Neurobiol Aging. 2012;33(5):1003.e1009-17.
52. Wersching H, Duning T, Lohmann H, Mohammadi S, Stehling C, Fobker M, et al. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology. 2010;74(13):1022-9.
53. Bettcher BM, Yaffe K, Boudreau RM, Neuhaus J, Aizenstein H, Ding J, et al. Declines in inflammation predict greater white matter microstructure in older adults. Neurobiol Aging. 2015;36(2):948-54.
54. Vilar-Bergua A, Riba-Llena I, Nafria C, Bustamante A, Llombart V, Delgado P, et al. Blood and CSF biomarkers in brain subcortical ischemic vascular disease: involved pathways and clinical applicability. J Cereb Blood Flow Metab. 2016;36(1):55-71.
55. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999;19(4):223-30.
56. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002;23(2):237-43.
57. Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, et al. Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement Geriatr Cogn Dis Extra. 2011;1(1):31-42.
58. Ozturk C, Ozge A, Yalin OO, Yilmaz IA, Delialioglu N, Yildiz C. Tet al. The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: correlation with cognitive and functional decline. Behav Neurol. 2007;18(4):207-15.
59. Olsson B, Hertze J, Lautner R, Zetterberg H, Nagga K, Hoglund K, et al. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2013;33(1):45-53.
60. Weekman EM, Wilcock DM. Matrix metalloproteinase in blood-brain barrier breakdown in dementia. J Alzheimers Dis. 2016;49(4):893-903.
61. Rosenberg GA. Matrix metalloproteinase-mediated Neuroinflammation in vascular cognitive impairment of the Binswanger type. Cell Mol Neurobiol. 2016;36(2):195-202.
62. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, et al. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke. 2004;35(6):e159-62.
63. Candelario-Jalil E, Thompson J, Taheri S, Grossetete M, Adair JC, Edmonds E, et al. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke. 2011;42(5):1345-50.
64. Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A. 1987;84(10):3472-6.
65. Perrot R, Berges R, Bocquet A, Eyer J. Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol. 2008;38(1):27-65.
66. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67(5):2013-8.
67. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett. 2002;320(3):156-60.
68. Norgren N, Karlsson JE, Rosengren L, Stigbrand T. Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics. 2002;21(1):53-9.
69. Gresle MM, Butzkueven H, Shaw G. Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis. Mult Scler Int. 2011;2011:315406.
70. Friede RL, Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec. 1970;167(4):379-87.
71. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001;66(3):510-6.
72. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord. 2009;28(4):348-56.
73. Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, et al. Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol. 2010;17(3):377-82.
74. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003;987(1):25-31.
75. Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83(21):1945-53.
76. Petzold A, Keir G, Warren J, Fox N, Rossor MN. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis. 2007;4(2-3):185-94.
77. Bjerke M, Jonsson M, Nordlund A, Eckerstrom C, Blennow K, Zetterberg H, et al. Cerebrovascular biomarker profile is related to white matter disease and ventricular dilation in a LADIS Substudy. Dement Geriatr Cogn Dis Extra. 2014;4(3):385-94.
78. Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;21(5-6):291-5.
79. Omlin FX, Webster HD, Palkovits CG, Cohen SR. Immunocytochemical localization of basic protein in major dense line regions of central and peripheral myelin. J Cell Biol. 1982;95(1):242-8.
80. Yin X, Crawford TO, Griffin JW, Tu P, Lee VM, Li C, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci. 1998;18(6):1953-62.
81. Wallin A, Blennow K, Uhlemann C, Langstrom G, Gottfries CG. White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia--diagnostic and pathogenetic aspects. Acta Neurol Scand. 1989;80(6):518-23.
82. Kalaria RN, Erkinjuntti T. Small vessel disease and subcortical vascular dementia. J Clin Neurol. 2006;2(1):1-11.
83. Brouns R, De Vil B, Cras P, De Surgeloose D, Marien P, De Deyn PP. Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients. Clin Chem. 2010;56(3):451-8.
84. Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND, et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis. 2014;6:51-8.
85. Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG, Svennerholm L. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurol Scand. 1992;85(2):103-6.
86. Tullberg M, Mansson JE, Fredman P, Lekman A, Blennow K, Ekman R, et al. CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry. 2000;69(1):74-81.
87. Jonsson M, Zetterberg H, Rolstad S, Edman A, Gouw AA, Bjerke M, et al. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: the LADIS study. Dement Geriatr Cogn Disord. 2012;34(1):61-7.
88. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol. 2003;54(1):115-9.
89. Tarkowski E, Tullberg M, Fredman P, Wikkelso C. Correlation between intrathecal sulfatide and TNF-alpha levels in patients with vascular dementia. Dement Geriatr Cogn Disord. 2003;15(4):207-11.
90. Zetterberg H, Lautner R, Skillback T, Rosen C, Shahim P, Mattsson N, et al. CSF in Alzheimer's disease. Adv Clin Chem. 2014;65:143-72.
91. Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, et al. The road ahead to cure Alzheimer's disease: development of biological markers and Neuroimaging methods for prevention trials across all stages and target populations. J Prev Alzheimers Dis. 2014;1(3):181-202.
92. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9.
93. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-29.
94. Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett. 1995;186(2-3):181-3.
95. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol. 2003;10(2):119-28.
96. Paraskevas GP, Kapaki E, Liappas I, Theotoka I, Mamali I, Zournas C, et al. The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol. 2005;18(3):163-73.
97. Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1995;59(3):280-3.
98. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58(3):373-9.
99. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998;64(3):298-305.
100. Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett. 2005;383(1-2):12-6.
101. Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, Koch G, et al. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci. 2005;237(1-2):83-8.
102. Leszek J, Malyszczak K, Janicka B, Kiejna A, Wiak A. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia. Med Sci Monit. 2003;9(11):CR484-8.
103. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, Zalonis I, et al. CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol. 2009;16(2):205-11.
104. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61(5):1828-34.
105. Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 1995;45(4):788-93.
106. Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis. J Neurol. 2013;260(11):2722-7.
107. Hermann P, Romero C, Schmidt C, Reis C, Zerr I. CSF biomarkers and neuropsychological profiles in patients with cerebral small-vessel disease. PLoS One. 2014;9(8):e105000.
108. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, Ohrfelt A, et al. Alzheimer's disease-subcortical vascular disease spectrum in a hospital-based setting: overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab. 2016;36(1):95-113.
109. Rosenberg GA, Prestopnik J, Adair JC, Huisa BN, Knoefel J, Caprihan A, et al. Validation of biomarkers in subcortical ischaemic vascular disease of the Binswanger type: approach to targeted treatment trials. J Neurol Neurosurg Psychiatry. 2015;86(12):1324-30.
110. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging. 2004;25(3):273-81.
111. Chasseigneaux S, Allinquant B. Functions of Abeta, sAPPalpha and sAPPbeta: similarities and differences. J Neurochem. 2012;120(Suppl 1):99-108.
112. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. NeuroMolecular Med. 2012;14(1):65-73.
113. Kohriyama T, Yamaguchi S, Tanaka E, Yamamura Y, Nakamura S. Coagulation and fibrinolytic parameters as predictors for small-vessel disease revealed by magnetic resonance imaging of the brain. Rinsho Shinkeigaku. 1996;36(5):640-7.
114. Wiseman S, Marlborough F, Doubal F, Webb DJ, Wardlaw J. Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis. 2014;37(1):64-75.
115. Ritz MF, Grond-Ginsbach C, Kloss M, Tolnay M, Fluri F, Bonati LH, et al. Identification of inflammatory, metabolic, and cell survival pathways contributing to cerebral small vessel disease by postmortem gene expression microarray. Curr Neurovasc Res. 2016;13(1):58-67.
116. Kilpatrick TJ, Matkovic Z, Davis SM, McGrath CM, Dauer RJ. Hematologic abnormalities occur in both cortical and lacunar infarction. Stroke. 1993;24(12):1945-50.
117. Bath PM, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets. 1998;9(3-4):155-9.
118. Salobir B, Sabovic M, Peternel P, Stegnar M, Grad A. Classic risk factors, hypercoagulability and migraine in young women with cerebral lacunar infarctions. Acta Neurol Scand. 2002;105(3):189-95.
119. Jood K, Danielson J, Ladenvall C, Blomstrand C, Jern C. Fibrinogen gene variation and ischemic stroke. J Thromb Haemost. 2008;6(6):897-904.
120. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J Neurol Neurosurg Psychiatry. 2011;82(9):986-92.
121. Beer C, Blacker D, Hankey GJ, Puddey IB. Association of clinical and aetiologic subtype of acute ischaemic stroke with inflammation, oxidative stress and vascular function: a cross-sectional observational study. Med Sci Monit. 2011;17(9):CR467-73.
122. Zhang B, Zhang W, Li X, Pu S, Yin J, Yang N, et al. Admission markers predict lacunar and non-lacunar stroke in young patients. Thromb Res. 2011;128(1):14-7.
123. Vischer UM. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-93.
124. Isenegger J, Meier N, Lammle B, Alberio L, Fischer U, Nedeltchev K, et al. D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis. 2010;29(1):82-6.
125. Kario K, Matsuo T, Kobayashi H, Hoshide S, Shimada K. Hyperinsulinemia and hemostatic abnormalities are associated with silent lacunar cerebral infarcts in elderly hypertensive subjects. J Am Coll Cardiol. 2001;37(3):871-7.
126. Kearney-Schwartz A, Rossignol P, Bracard S, Felblinger J, Fay R, Boivin JM, et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke. 2009;40(4):1229-36.
127. Nagai M, Hoshide S, Kario K. Association of prothrombotic status with markers of cerebral small vessel disease in elderly hypertensive patients. Am J Hypertens. 2012;25(10):1088-94.
128. Colombatti R, De Bon E, Bertomoro A, Casonato A, Pontara E, Omenetto E, et al. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One. 2013;8(10):e78801.
129. Salmaggi A, Gelati M, Dufour A, Corsini E, Pagano S, Baccalini R, et al. Expression and modulation of IFN-gamma-inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J Interf Cytokine Res. 2002;22(6):631-40.
130. de Leeuw FE, de Kleine M, Frijns CJ, Fijnheer R, van Gijn J, Kappelle LJ. Endothelial cell activation is associated with cerebral white matter lesions in patients with cerebrovascular disease. Ann N Y Acad Sci. 2002;977:306-14.
131. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285-95.
132. Han JH, Wong KS, Wang YY, Fu JH, Ding D, Hong Z. Plasma level of sICAM-1 is associated with the extent of white matter lesion among asymptomatic elderly subjects. Clin Neurol Neurosurg. 2009;111(10):847-51.
133. Rouhl RP, Damoiseaux JG, Lodder J, Theunissen RO, Knottnerus IL, Staals J, et al. Vascular inflammation in cerebral small vessel disease. Neurobiol Aging. 2012;33(8):1800-6.
134. Craggs LJ, Hagel C, Kuhlenbaeumer G, Borjesson-Hanson A, Andersen O, Viitanen M, et al. Quantitative vascular pathology and phenotyping familial and sporadic cerebral small vessel diseases. Brain Pathol. 2013;23(5):547-57.
135. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol. 2002;12(3):358-70.
136. Giwa MO, Williams J, Elderfield K, Jiwa NS, Bridges LR, Kalaria RN, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology. 2012;78(3):167-74.
137. Hainsworth AH, Oommen AT, Bridges LR. Endothelial cells and human cerebral small vessel disease. Brain Pathol. 2015;25(1):44-50.
138. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004;127(Pt 1):212-9.
139. Pavlovic AM, Pekmezovic T, Obrenovic R, Novakovic I, Tomic G, Mijajlovic M, et al. Increased total homocysteine level is associated with clinical status and severity of white matter changes in symptomatic patients with subcortical small vessel disease. Clin Neurol Neurosurg. 2011;113(9):711-5.
140. Hainsworth AH, Yeo NE, Weekman EM, Wilcock DM. Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID). Biochim Biophys Acta. 2016;1862(5):1008-17.
141. Kondziella D, Gothlin M, Fu M, Zetterberg H, Wallin A. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. Neuroreport. 2009;20(9):825-7.
142. Mirza SS, de Bruijn RF, Koudstaal PJ, van den Meiracker AH, Franco OH, Hofman A, et al. The N-terminal pro B-type natriuretic peptide, and risk of dementia and cognitive decline: a 10-years follow-up study in the general population. J Neurol Neurosurg Psychiatry. 2016;87(4):356-62.
143. Schneider AL, Rawlings AM, Sharrett AR, Alonso A, Mosley TH, Hoogeveen RC, et al. High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J. 2014;35(27):1817-24.
144. Pikula A, Boger RH, Beiser AS, Maas R, DeCarli C, Schwedhelm E, et al. Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke. 2009;40(9):2959-64.
145. Tsai NW, Chang YT, Huang CR, Lin YJ, Lin WC, Cheng BC, et al. Association between oxidative stress and outcome in different subtypes of acute ischemic stroke. Biomed Res Int. 2014;2014:256879.
146. Wallin A, Ohrfelt A, Bjerke M. Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. J Neurol Sci. 2012;322(1-2, 192):-16.
147. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand. 1990;81(4):323-6.
148. Frolich L, Kornhuber J, Ihl R, Fritze J, Maurer K, Riederer P. Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG. Eur Arch Psychiatry Clin Neurosci. 1991;240(6):363-6.
149. Mroczko B, Groblewska M, Zboch M, Kulczynska A, Koper OM, Szmitkowski M, et al. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. J Alzheimers Dis. 2014;40(2):351-7.
150. Horstmann S, Budig L, Gardner H, Koziol J, Deuschle M, Schilling C, et al. Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr. 2010;22(6):966-72.
151. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int. 2001;39(5-6):409-13.
152. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G, et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett. 2003;336(3):167-70.
153. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry. 2010;68(10):903-12.
154. Huang CW, Tsai MH, Chen NC, Chen WH, Lu YT, Lui CC, et al. Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer's dementia. Thromb Haemost. 2015;114(6):1230-40.
155. Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M, et al. Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers. Food Chem Toxicol. 2013;61:209-14.
156. Rosenberg GA, Wallin A, Wardlaw JM, Markus HS, Montaner J, Wolfson L, et al. Consensus statement for diagnosis of subcortical small vessel disease. J Cereb Blood Flow Metab. 2016;36(1):6-25.
157. Ravid R. The uniqueness of biobanks for neurological and psychiatric diseases: potentials and pitfalls. Pathobiology. 2014;81(5-6):237-44.